1800 244 735

Helpline (02) 9874 9777

Huntingtin takes a trip: harmful proteins pass between brain cells

Clumps of mutant huntingtin protein in brain cells are a hallmark of HD, and they build up slowly, occupying more and more cells over time. Recent research in mice shows that the harmful proteins can travel between neurons, setting off a chain reaction that leads to more sick cells and the development of symptoms.

An aggregate invasion

A person diagnosed with a neurodegenerative disease, such as Huntington’s, Alzheimer’s, or Parkinson’s, will develop symptoms progressively, meaning that they begin gradually and worsen over time. The progressive nature of Huntington’s is reflected within the brain, where cells controlling mood and movement become vulnerable to damage, then decrease in numbers over the course of many years. At the same time, neurons all over the brain slowly become littered with clumps of biological trash.

These harmful clumps, often called “aggregates,” contain abnormal huntingtin protein along with other sticky gunk. Even though every cell in an affected person’s brain contains the HD mutation, aggregates don’t show up everywhere all at once – they appear in a small percentage of cells at first, and eventually become widespread throughout the brain. The question of how this massive buildup occurs is the subject of ongoing research.

A recent study provides strong evidence that an affected cell can pass mutant huntingtin on to its neighbors, by oozing the protein into the vicinity of unsuspecting healthy cells. In turn, these cells then develop aggregates and succumb to their harmful effects. In unaffected mice, a transplant of cells containing the HD mutation was toxic enough to induce HD-like behavioral symptoms. This finding has important implications for the design of current and future therapeutics for HD.

Harmful proteins can be transmitted cell-to-cell

The mutation at the root of Huntington’s disease causes a single protein, huntingtin, to be extra-long and difficult to fold. Compare the task of folding a big pile of fitted sheets versus flat top sheets – one is more likely to lengthen your laundry day. You can choose to leave your sheets in a big jumble, but proteins need proper folding into the correct 3D shapes to function optimally. When this fails, misfolded proteins build up and cause lasting damage, the scourge of neurons in almost every known brain disease.

In a person with HD, the mutation is present in every part of the brain and body, so each individual cell has the huntingtin misfolding problem on its hands. For reasons we don’t understand, some cells succumb early to this setback and accumulate harmful clumps of mutant huntingtin. Others develop these aggregates much later, or not at all. The idea that an aggregate forms independently in each cell is called “cell-autonomous” aggregation, and this was the assumption of brain scientists for many years. In just the past decade, however, a “non-cell-autonomous” theory has emerged, where aggregates formed in one cell can be transmitted to neighboring cells.

This phenomenon has been observed in petri dishes and in mouse models of other neurodegenerative disorders, including Alzheimer’s, Parkinson’s, and ALS. In the HD field, several studies have hinted that mutant huntingtin protein can pass from cell to cell, both in dishes and even in humans. Recently, a group of trans-global collaborators in Korea and Canada showed more definitively that cells can actually release mutant huntingtin onto healthy neighbors and make them sick.

Traveling aggregates, ailing brain

Researchers led by Jihwan Song at CHA University in Korea began by obtaining fibroblasts from volunteer HD patients. Fibroblasts are a type of skin cell that scientists can grow in a dish and experiment on directly, or they can amazingly be “reprogrammed” to resemble brain cells. The research team did surgery to implant HD fibroblasts or reprogrammed nerve cells into the brains of healthy newborn mice, which developed and grew into adulthood normally.

But around eight months later – middle age for a mouse – the scientists began to see signs of illness. The mice slowly developed problems with movement and thinking, like difficulty navigating through a water maze, and weakness in their limbs. Their brains showed signs of sick and dying cells in the striatum, the most vulnerable region in Huntington’s disease. From a graft of human cells carrying the HD mutation, totally normal mice had developed behaviors and pathology reminiscent of HD.

A striking observation was that the mouse brain cells, which did not carry the HD mutation, had developed huntingtin aggregates! This is strong evidence that the implanted mutant cells were able to pass abnormal huntingtin protein to their healthy neighbors, effectively getting them sick.

Exosomes: a biological postal service

So how can a mutant protein spread between cells like an infection? The answer may lie in tiny messenger compartments called exosomes. These are structures that help neighboring cells communicate by sharing chemicals and proteins. Cells are encased in membranes, curved fatty barriers against the outside, like a big bubble. The membrane can pinch off a teeny tiny portion of itself to form a new little bubble, packed with cargo it wants to send to a cell down the lane. The little bubble merges with a new cell, and pop! The contents are now inside that cell.

To understand how the implanted HD cells were able to infect their neighbors, the scientists grew HD skin cells alongside healthy cells in dishes. When cells are grown in a dish in the laboratory, they live submerged in a bath of nutrients, so when exosomes are released, they enter the bath. Just like in the mouse brains, the neighbors of HD fibroblasts began to show signs of sickness – and they eventually developed huntingtin aggregates. Floating in the bathwater from the HD cells were exosomes containing mutant huntingtin, which merged with healthy cells, exposing them to harmful misfolded protein.

The final evidence that exosomes were the culprit came from another experiment in mice. The researchers isolated exosomes from the bathwater of HD fibroblasts using a series of pressure and filtration steps, the chemical equivalent of draining pasta through a strainer, on a microscopic scale. When they separated out the HD exosomes and transplanted them into the brains of newborn mice, those mice grew up and developed huntingtin aggregates as well as behavioral signs of HD. So mutant huntingtin proteins can travel from cell-to-cell via exosomes, infecting one another and perhaps speeding up the buildup of harmful aggregates.

Vital information for the future of HD therapy

This study is a clear example of how an improperly folded disease protein can trigger a chain reaction in healthy cells, making them sick, too. In the HD brain, it’s possible that some misfolded mutant huntingtin gets packaged into exosomes because it’s simply a way to unload an insurmountable pile of laundry. When a sick cell’s neighbor is already genetically vulnerable because it too has the HD mutation, receiving that extra pile of work could push it over the edge, leading it to develop its own aggregates.

The results of this work are extremely informative for the design of current and future therapies for HD. In particular, our approaches to cell replacement therapy and gene silencing will be shaped by the knowledge that mutant huntingtin can travel between cells. The tactic of cell replacement therapy – filling in brain areas damaged by HD with new, healthy cells – may unfortunately be impractical, if the new cells are likely to acquire aggregates from their neighbors and become sick.

As for gene silencing (shutting off the HD gene), some of our current approaches involve localized delivery of drugs to a vulnerable part of the brain. This approach has been promising, but it’s extremely difficult to get a drug into every single cell. We will have to take into account that it could be possible for untreated cells to pass mutant huntingtin back into treated cells, undermining the treatment. Well-designed research showing that cell-to-cell transfer of abnormal huntingtin is plausible has provided an essential piece of information that will extend our ability to develop and assess future therapies. Finally, using this knowledge to stop the spread of aggregates is a new avenue to investigate in HD.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Scientists identify precisely how pridopidine works in models of Huntington’s disease

Published date: 12 June, 2021

Pridopidine is a drug developed to treat Huntington’s disease (HD) and now scientists have a clearer understanding of how it works in the body and brain. In a series of academic papers, researchers figured out that pridopidine is working by targeting a particular receptor protein called S1R. With this new understanding, the researchers believe pridopidine ... Read more

Huntington's disease therapeutics conference 2021 – Day 3

Published date: 29 April, 2021

We are back for the last day of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can find with the hashtag #HDTC2021. The final session of the conference will provide the latest news on more Huntington’s disease clinical programs. A new way ... Read more

Huntington's disease therapeutics conference 2021 – Day 2

Published date: 28 April, 2021

We are back with Day 2 of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning session focussed on promising HD therapeutics that are in preclinical development and the afternoon session covered different ... Read more

Huntington’s disease therapeutics conference 2021 – Day 1

Published date: 28 April, 2021

The CHDI Therapeutics Conference 2021 kicked off today. This article summarizes our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning of Day 1 focused on clinical trial updates, while the afternoon explored genetic modifiers of HD and how they might be harnessed ... Read more

Huntington’s disease clinical trial round up

Published date: 26 April, 2021

It seems like the HD community has been inundated with updates from different companies and clinical trials recently. The news is far from complete doom and gloom; although there have been some real disappointments from some of the frontrunner trials, there are also positive updates from many different companies and lots of reasons for us ... Read more

Good news from uniQure: gene therapy trial on track, and promising data in animals

Published date: 15 April, 2021

Two recent press releases from uniQure provide welcome good news: the first ever HD gene therapy, known as AMT-130, has been administered via brain surgery to a small set of participants in an early safety trial. At the same time, uniQure has published findings in HD animal models that increase confidence in the drug’s ability ... Read more